MAZE Maze Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: MAZE

Price (delayed)

$28.09

Market cap

$1.56B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.47

Enterprise value

$1.42B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 37
Highlights
The EPS has soared by 83% YoY
The company's equity has surged by 73% YoY and by 33% QoQ
Maze Therapeutics's net income has increased by 21% YoY but it has decreased by 9% from the previous quarter
MAZE's debt has surged by 142% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: https://www.mazetx.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of MAZE

MAZE stock price

How has the Maze Therapeutics stock price performed over time
Intraday
-1.02%
1 week
17.46%
1 month
-4.55%
1 year
12.9%
YTD
-32.2%
QTD
-5.86%

Financial performance

How have Maze Therapeutics's revenue and profit performed over time
Revenue
$20M
Gross profit
$20M
Operating income
-$145.61M
Net income
-$133.59M
Gross margin
100%
Net margin
-668%
MAZE's net margin has surged by 90% year-on-year but it is down by 9% since the previous quarter
MAZE's operating margin has surged by 86% year-on-year but it is down by 9% since the previous quarter
Maze Therapeutics's net income has increased by 21% YoY but it has decreased by 9% from the previous quarter
MAZE's operating income is down by 16% YoY and by 9% from the previous quarter

Price vs fundamentals

How does MAZE's price correlate with its fundamentals

Growth

What is Maze Therapeutics's growth rate over time

Valuation

What is Maze Therapeutics stock price valuation
P/E
N/A
P/B
3.43
P/S
82.86
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
70.85
The EPS has soared by 83% YoY
The company's equity has surged by 73% YoY and by 33% QoQ
The stock's price to book (P/B) is 17% less than its last 4 quarters average of 4.2

Efficiency

How efficient is Maze Therapeutics business performance
The ROS has soared by 90% YoY but it has contracted by 8% from the previous quarter
Maze Therapeutics's return on invested capital has surged by 80% YoY and by 29% QoQ
MAZE's return on assets is up by 16% year-on-year and by 5% since the previous quarter
Maze Therapeutics's ROE has increased by 4.6% from the previous quarter

Dividends

What is MAZE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MAZE.

Financial health

How did Maze Therapeutics financials performed over time
MAZE's total liabilities has surged by 90% year-on-year
The total assets has surged by 75% year-on-year and by 27% since the previous quarter
MAZE's debt is 87% smaller than its equity
MAZE's debt has surged by 142% year-on-year
The company's equity has surged by 73% YoY and by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.